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Cover image: How do stem cells know where to go. Human stem cells use the local responses to a vascular injury (aggregation of platelets) to 
home to an injury under flow. Injury-associated factors (VEGF, SDF) mediate differentiation of the stem cells towards an endothial phenotype 
(expression of VEGFR-2, CD31 etc). Image: endothelial cells (#) were stimulated with TNF-alpha to make them pro-coagulant. Platelet-rich 
plasma was pre-perfused over the endothelial cells to let the platelets adhere and aggregate (+), leading to the expression of P-selectin. 
Next, CD34+ cells (*) were perfused and were shown to adhere to the activated platelets through binding to PSGL-1 expressed by the stem 
cells. Human CD34+/KDR+ cells are generated from circulating CD34+ cells after immobilization on activated platelets. (de Boer HC, Hovens 
MM, van Oeveren-Rietdijk AM, Snoep JD, de Koning EJ, Tamsma JT, Huisman MV, Rabelink AJ, van Zonneveld AJ. Arterioscler Thromb Vasc Biol. 
2011 Feb;31(2):408-15. Epub 2010 Oct 28.)
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